Odisha Approves Pharma & MedTech Policy to Build Sector Hubs & Boost Investment

The new policy will help Odisha build a competitive ecosystem for pharmaceutical and MedTech manufacturing, offering investors modern infrastructure, incentives and streamlined approvals to scale operations.

The Odisha Cabinet has approved a new Pharma & MedTech Policy designed to position the state as a competitive hub for pharmaceutical manufacturing, medical device production, and healthcare innovation.

The policy is expected to drive large-scale investment and accelerate the development of sector-specific industrial clusters equipped with advanced infrastructure and streamlined regulatory processes.

Announcing the approval, Chief Secretary Pradeep Kumar Jena said the new policy will give Odisha a stronger presence in India’s expanding healthcare manufacturing landscape. “The Pharma and MedTech sector have significant potential for growth,” he noted.

Adding that the policy aims to support investors with incentives, land availability and plug-and-play facilities to help companies scale faster.

The initiative includes the creation of dedicated industrial hubs to attract pharmaceutical companies, bulk drug manufacturers, diagnostic device producers and MedTech innovators.

Industries Secretary Hemant Sharma highlighted that the policy is designed to help Odisha tap into rising demand for domestic manufacturing. “We see this as an opportunity to build a reliable, high-quality ecosystem that supports both innovation and large-scale production,” he said.

By expanding manufacturing capacities within the state, Odisha aims to strengthen supply chains and provide a conducive environment for research, technology upgrades and global export opportunities.

The Cabinet also emphasized the policy’s potential to create high-skilled employment and foster industry-academia collaboration across pharmaceuticals and MedTech.

Hemant Sharma mentioned the state is prepared to offer investor-friendly support. “Our focus is on creating long-term value for companies and ensuring Odisha becomes a preferred destination for the life sciences sector.”

With the policy now in place, the government is expected to initiate development work within planned industrial zones and begin outreach to domestic and international manufacturers.

Related Posts

PGIMS recalls drug amid probe into deaths

The PGIMS authorities have directed all departments to immediately stop using a specific batch of injectable Propofol, an anaesthetic drug, and return the available stock to the central store. The…

NPPA list brings little relief: No price cut for 25% cancer drugs

Mumbai: Nearly one in four cancer drug packs in a revised price list issued by the National Pharmaceutical Pricing Authority (NPPA) has seen no reduction in maximum retail price (MRP),…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

PGIMS recalls drug amid probe into deaths

PGIMS recalls drug amid probe into deaths

NPPA list brings little relief: No price cut for 25% cancer drugs

NPPA list brings little relief: No price cut for 25% cancer drugs

Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

For Aakash Healthcare, Community People are Apples of its Eyes

For Aakash Healthcare, Community People are Apples of its Eyes

Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

Yashoda Medicity: Baby takes a Giant Step in just One Year

Yashoda Medicity: Baby takes a Giant Step in just One Year